USD 1.86
↓ -0.15 (-7.46%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| CLRB | -7.5 | -13.9 | -10.6 | -8.4 | -44.1 | -7 | -76.8 | -83.1 | -99.9 | -100.0 |
| S&P 500 | -1.3 | -2.3 | 0.5 | 5.7 | 10.8 | 30.2 | 24.9 | 88.0 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | CLRB |
| name | Cellectar Biosciences, Inc. |
| price | 1.86 |
| changes percentage | -7.46 |
| change | -0.15 |
| day low | 1.83 |
| day high | 2.02 |
| year high | 4.45 |
| year low | 1.82 |
| market cap | 75453690 |
| price avg 50 | 2.08 |
| price avg 200 | 2.79 |
| exchange | NASDAQ |
| volume | 1215005 |
| avg volume | 235840 |
| open | 2.01 |
| previous close | 2.01 |
| eps | -2.43 |
| pe | -0.77 |
| earnings announcement | 2024-11-18T13:30:00.000+0000 |
| shares outstanding | 40566500 |
| timestamp | 2024-11-15 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001279704 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -192375 | -238867 | 19.46 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 28211460 | 19219603 | 46.78 |
| operating expenses | 38960643 | 28813773 | 35.22 |
| interest income | 0 | 152519 | -100.00 |
| interest expense | 0 | -300954 | 100.00 |
| ebitda | -38768268 | -28665338 | -35.24 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -38960643 | -28813773 | -35.22 |
| operating income ratio | 0 | 0 | NaN |
| net income | -37983496 | -28601254 | -32.80 |
| net income ratio | 0 | 0 | NaN |
| eps | -3.11 | -4.05 | 23.21 |
Gross Profit: Gross Profit increased to 0 million in 2023 from 0 million in 2022 representing a change of 19.46%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 28 million in 2023 from 19 million in 2022 representing a change of 46.78%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -39 million in 2023 from -29 million in 2022 representing a change of -35.24%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -39 million in 2023 from -29 million in 2022 representing a change of -35.22%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -38 million in 2023 from -29 million in 2022 representing a change of -32.8%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -3.11 in 2023 from -3.11 in 2022 representing a change of 23.21%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 39 million in 2023 from 29 million in 2022 representing a change of 35.22%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001279704 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -66021 | -88490 | 25.39 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 7345480 | 7377940 | -0.44 |
| operating expenses | 13703709 | 11912996 | 15.03 |
| interest income | 328907 | 319849 | 2.83 |
| interest expense | 0 | 0 | NaN |
| ebitda | -13703709 | -11912996 | -15.03 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -13703709 | -12001490 | -14.18 |
| operating income ratio | 0 | 0 | NaN |
| net income | -919371 | -21581637 | 95.74 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.19 | -0.74 | 74.32 |
Gross Profit: Gross Profit increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 25.39%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -14 million in 2024Q2 from -12 million in 2024Q1 representing a change of -15.03%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -14 million in 2024Q2 from -12 million in 2024Q1 representing a change of -14.18%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -1 million in 2024Q2 from -22 million in 2024Q1 representing a change of 95.74%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.19 in 2024Q2 from -0.19 in 2024Q1 representing a change of 74.32%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 7 million in 2024Q2 from 7 million in 2024Q1 representing a change of -0.44%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 14 million in 2024Q2 from 12 million in 2024Q1 representing a change of 15.03%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001279704 | |||
| total assets | 12075580 | 21589790 | -44.07 |
| total liabilities | 13431627 | 6082271 | 120.83 |
| total equity | -1356047 | 15507519 | -108.74 |
| cash and cash equivalents | 9564988 | 19866358 | -51.85 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 10453213 | 20529601 | -49.08 |
| total non current assets | 1622367 | 1060189 | 53.03 |
| total current liabilities | 12937624 | 5529290 | 133.98 |
| total non current liabilities | 494003 | 552981 | -10.67 |
| common stock | 207 | 94 | 120.21 |
| retained earnings | -217482539 | -179499043 | -21.16 |
| total debt | 552982 | 603828 | -8.42 |
Total Assets: Total Assets decreased to 12 million in 2023 from 22 million in 2022 representing a change of -44.07%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 13 million in 2023 from 6 million in 2022 representing a change of 120.83%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -1 million in 2023 from 16 million in 2022 representing a change of -108.74%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 10 million in 2023 from 20 million in 2022 representing a change of -51.85%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 10 million in 2023 from 21 million in 2022 representing a change of -49.08%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 13 million in 2023 from 6 million in 2022 representing a change of 133.98%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -217 million in 2023 from -179 million in 2022 representing a change of -21.16%. This indicates an accumulated losses.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 120.21%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 1 million in 2023 from 1 million in 2022 representing a change of -8.42%. This indicates a reduction in overall debt burden.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001279704 | |||
| total assets | 29384657 | 42908439 | -31.52 |
| total liabilities | 15621661 | 16742293 | -6.69 |
| total equity | 12380973 | 26166146 | -52.68 |
| cash and cash equivalents | 25868907 | 40031181 | -35.38 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 27905360 | 41368365 | -32.54 |
| total non current assets | 1479297 | 1540074 | -3.95 |
| total current liabilities | 15168153 | 16267944 | -6.76 |
| total non current liabilities | 453508 | 474349 | -4.39 |
| common stock | 358 | 332 | 7.83 |
| retained earnings | -230322371 | -239064176 | 3.66 |
| total debt | 530856 | 548343 | -3.19 |
Total Assets: Total Assets decreased to 29 million in 2024Q2 from 43 million in 2024Q1 representing a change of -31.52%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 12 million in 2024Q2 from 26 million in 2024Q1 representing a change of -52.68%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 26 million in 2024Q2 from 40 million in 2024Q1 representing a change of -35.38%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 28 million in 2024Q2 from 41 million in 2024Q1 representing a change of -32.54%. This indicates a worsen liquidity position.
Total Liabilities: Total Liabilities decreased to 16 million in 2024Q2 from 17 million in 2024Q1 representing a change of -6.69%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 15 million in 2024Q2 from 16 million in 2024Q1 representing a change of -6.76%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024Q2 from 0 in 2024Q1 representing a change of 7.83%. This indicates an increase in ownership interest.
Retained Earnings: Retained Earnings increased to -230 million in 2024Q2 from -239 million in 2024Q1 representing a change of 3.66%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 1 million in 2024Q2 from 1 million in 2024Q1 representing a change of -3.19%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001279704 | |||
| net change in cash | -10301370 | -15837617 | 34.96 |
| operating cash flow | -32376974 | -25222301 | -28.37 |
| free cash flow | -33241012 | -25448272 | -30.62 |
| capital expenditure | -864038 | -225971 | -282.37 |
| depreciation and amortization | 192375 | 148435 | 29.60 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 2410288 | 1452.96 | 165,787.66 |
| accounts payables | 3700202 | 1623529 | 127.91 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -864038 | -225971 | -282.37 |
| net cash used for investing activites | -864038 | -225971 | -282.37 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 22939642 | 9610655 | 138.69 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 22939642 | 9610655 | 138.69 |
| cash at end of period | 9564988 | 19866358 | -51.85 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 19866358 | 35703975 | -44.36 |
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001279704 | |||
| operating cash flow | -14140999 | -13361641 | -5.83 |
| free cash flow | -14162275 | -13383274 | -5.82 |
| capital expenditure | -21276 | -21633 | 1.65 |
| depreciation and amortization | 66021 | 88490 | -25.39 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 799250 | 454.36 | 175,805.61 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -930742 | -1784695 | 47.85 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -21276 | -21633 | 1.65 |
| net cash used for investing activites | -21276 | -21633 | 1.65 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -43849467 | 43849467 | -200.00 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 1 | 43849467 | -100.00 |
| net change in cash | -14162274 | 30466193 | -146.49 |
| cash at end of period | 25868907 | 40031181 | -35.38 |
| cash at beginning of period | 40031181 | 9564988 | 318.52 |
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q2 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -3.11 | -4.05 | 23.33 |
| operating cash flow per share | -2.65 | -3.57 | 25.89 |
| free cash flow per share | -2.72 | -3.61 | 24.59 |
| cash per share | 0.78 | 2.82 | -72.20 |
| book value per share | -0.11 | 2.2 | -105.05 |
| tangible book value per share | -0.11 | 2.2 | -105.05 |
| shareholders equity per share | -0.11 | 2.2 | -105.05 |
| interest debt per share | 0.0 | -0.04 | 113.61 |
| market cap | 33853751.67 | 12065187.15 | 180.59 |
| enterprise value | 24841745.67 | -7197342.85 | 445.15 |
| pe ratio | -0.89 | -0.42 | -111.28 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -1.05 | -0.48 | -118.59 |
| pfcf ratio | -1.02 | -0.47 | -114.81 |
| pb ratio | -24.97 | 0.78 | -3,308.78 |
| ptb ratio | -24.97 | 0.78 | -3,308.78 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -0.64 | 0.25 | -355.21 |
| ev to operating cash flow | -0.77 | 0.29 | -368.88 |
| ev to free cash flow | -0.75 | 0.28 | -364.24 |
| earnings yield | -1.12 | -2.37 | 52.67 |
| free cash flow yield | -0.98 | -2.11 | 53.45 |
| debt to equity | -0.04 | 0.0 | -1,426.48 |
| debt to assets | 0.0 | 0.0 | 107.38 |
| net debt to ebitda | 0.23 | 0.67 | -65.41 |
| current ratio | 0.81 | 3.71 | -78.24 |
| interest coverage | 0 | 95.74 | -100.00 |
| income quality | 0.85 | 0.88 | -3.34 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.03 | -0.01 | -197.87 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 4.49 | 1.52 | 195.03 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 2.79 | 14.16 | -80.33 |
| roic | 29.99 | -1.85 | 1,722.75 |
| return on tangible assets | -3.15 | -1.32 | -137.44 |
| graham net net | -0.32 | 1.95 | -116.19 |
| working capital | -2484411 | 15000311 | -116.56 |
| tangible asset value | -1356047 | 15507519 | -108.74 |
| net current asset value | -2978414 | 14447330 | -120.62 |
| invested capital | -891824 | 15979286 | -105.58 |
| average receivables | 0 | 0 | NaN |
| average payables | 4089000 | 1986500 | 105.84 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 10663.03 | 3908.74 | 172.80 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.03 | 0.09 | -63.34 |
| inventory turnover | 0 | 0 | NaN |
| roe | 28.01 | -1.84 | 1,618.72 |
| capex per share | 0.07 | 0.03 | 120.75 |
ROE: Return on Equity (ROE) increased to 28.01 on 2023-12-31 from -1.84 on 2022-12-31, representing a change of 1618.72%. Suggesting the company has been generating high returns for its shareholders.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -0.04 on 2023-12-31 from 0.00 on 2022-12-31, representing a change of -1426.48%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -0.89 on 2023-12-31 from -0.42 on 2022-12-31, representing a change of -111.28%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.81 on 2023-12-31 from 3.71 on 2022-12-31, representing a change of -78.24%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| CLRB | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.03 | -0.74 | 96.51 |
| operating cash flow per share | -0.39 | -0.46 | 13.29 |
| free cash flow per share | -0.4 | -0.46 | 13.30 |
| cash per share | 0.72 | 1.36 | -47.06 |
| book value per share | 0.38 | 0.89 | -56.91 |
| tangible book value per share | 0.38 | 0.89 | -56.91 |
| shareholders equity per share | 0.35 | 0.89 | -61.23 |
| interest debt per share | 0.0 | 0.0 | -14.36 |
| market cap | 91339541.4 | 115038981.68 | -20.60 |
| enterprise value | 66001490.4 | 75556143.68 | -12.65 |
| pe ratio | -24.84 | -1.33 | -1,763.83 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -6.46 | -8.61 | 24.98 |
| pfcf ratio | -6.45 | -8.6 | 24.97 |
| pb ratio | 7.38 | 4.4 | 67.80 |
| ptb ratio | 7.38 | 4.4 | 67.80 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -4.82 | -6.34 | 24.06 |
| ev to operating cash flow | -4.67 | -5.65 | 17.46 |
| ev to free cash flow | -4.66 | -5.65 | 17.45 |
| earnings yield | -0.01 | -0.19 | 94.63 |
| free cash flow yield | -0.16 | -0.12 | -33.28 |
| debt to equity | 0.01 | 0.0 | 120.92 |
| debt to assets | 0.0 | 0.0 | 52.64 |
| net debt to ebitda | 1.85 | 3.31 | -44.21 |
| current ratio | 1.84 | 2.54 | -27.65 |
| interest coverage | 0 | 0 | NaN |
| income quality | 2.36 | 0.62 | 281.97 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | 7.07 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.32 | 0.24 | 31.82 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0.45 | 3.84 | -88.37 |
| roic | -1.1 | -0.46 | -139.99 |
| return on tangible assets | -0.03 | -0.5 | 93.78 |
| graham net net | 0.29 | 0.79 | -63.95 |
| working capital | 12737207 | 25100421 | -49.26 |
| tangible asset value | 13762996 | 26166146 | -47.40 |
| net current asset value | 12283699 | 24626072 | -50.12 |
| invested capital | 14186724 | 26610715 | -46.69 |
| average receivables | 0 | 0 | NaN |
| average payables | 6928579 | 6506975 | 6.48 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 8810.66 | 7520.12 | 17.16 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.01 | 0.01 | -14.65 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.07 | -0.82 | 91.00 |
| capex per share | 0.0 | 0.0 | -19.42 |
ROE: Return on Equity (ROE) increased to -0.07 on 2024-06-30 Q2 from -0.82 on 2024-03-31 Q1, representing a change of 91.00%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -24.84 on 2024-06-30 Q2 from -1.33 on 2024-03-31 Q1, representing a change of -1763.83%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.84 on 2024-06-30 Q2 from 2.54 on 2024-03-31 Q1, representing a change of -27.65%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.01 on 2024-06-30 Q2 from 0.00 on 2024-03-31 Q1, representing a change of 120.92%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 0.74 which is lower than current price 1.86, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Neutral
Publish Date: 2024-11-14 08:05:00
NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs
Sentiment: Negative
Publish Date: 2024-11-12 08:05:00
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025
Sentiment: Negative
Publish Date: 2024-11-11 16:05:00
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time.
Sentiment: Positive
Publish Date: 2024-11-07 06:40:00
Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study
Sentiment: Positive
Publish Date: 2024-11-01 17:00:00
FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced today it received a letter dated October 31, 2024, from Nasdaq, Inc. informing the Company that it had regained compliance with Nasdaq Listing Rule 5250(c)(1). The Company filed the following on October 29, 2024, with the Securities and Exchange Commission: (i) restated audited consolidated financial statements for the fiscal years ended December 31, 2023 and 2022 and restated quarterly financial statements for the periods ended March 31, 2023; June 30, 2023; September 30, 2023; March 31, 2022, June 30, 2022, and September 30, 2022 on Form 10-K/A; (ii) restated quarterly consolidated financial statements for the three months ended March 31, 2024 on Form 10-Q/A; and (iii) quarterly financial statements for the three and six months ended June 30, 2024 on Form 10-Q. The letter from Nasdaq noted that the matter is now closed.
Sentiment: Neutral
Publish Date: 2024-08-30 14:42:04
CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.
Sentiment: Neutral
Publish Date: 2024-08-26 06:40:00
Jorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D.
Sentiment: Negative
Publish Date: 2024-08-23 17:00:00
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the Company had received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) on August 20, 2024. The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Second Quarter 10-Q”), by the applicable due date.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
